CHESHIRE, UK--(MARKET WIRE)--Oct 28, 2008 --

 

                         Protherics PLC


             Notification of Directors' Interests


London, UK; Brentwood, TN, US: 28 October 2008 - Protherics PLC
("Protherics" or the "Company"), the international
biopharmaceutical
company focused on critical care and cancer, in accordance with
the FSA
Disclosure and Transparency Rules, announces that, on 23 October
2008, pursuant to the conversion of all outstanding six per cent.
unsecured convertible loan notes 2010 of Protherics, the following
ordinary shares (the "Shares") were allotted to Directors of
Protherics
PLC:


Director   Nominal Value of Loan    Shares allotted share
%
                 Notes converted                  capital
issued

Andrew Heath           GBP24,242                   96,968
0.028%
Stuart Wallis          GBP60,606                  242,424
0.069%In
 accordance with the Loan Note Instrument, the Shares were
allotted
at a price of 25 pence per share.


Following the above allotment of Shares, their interests in the
ordinary share capital of the Company are as follows:


                         No. Shares     % issued share capital

Andrew Heath                516,778                     0.148%
Stuart Wallis               809,113                     0.231%



                          / Ends /


For further information please contact:


Protherics
Nick Staples, Director of Corporate Affairs   +44 (0) 7919 480510
Julie Vickers, Company Secretary              +44 (0)1928 518010


Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott                 +44 (0) 20 7831 3113
New York: John Capodanno                      +1 212 850 5600



Or visit  http://www.protherics.com

                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

     Contacts:
     RNS
     Customer
     Services
     0044-207797-4400
     Email Contact
     http://www.rns.com